Q:

How Well Did Mannkind's Stock Perform in 2014?

A:

Quick Answer

MannKind's stock price fluctuated in 2014, performing extremely well at times but dropping to less than $6 in late December, explains The Motley Fool. At one point, the stock was worth more than $11 a share, about three times the value of its lowest price of $3.80.

Continue Reading
Related Videos

Full Answer

MannKind shareholders had expected more in 2014, notes The Motley Fool. Afrezza, the company's top product, received Food and Drug Administration approval for diabetes type 1 and type 2 patients. However, MannKind spent a lot of money to develop Afrezza, and it may never earn enough profits to offset its deficit of nearly $2.5 billion.

Learn more about Investing
Sources:

Related Questions

Explore